Clinical Trial Update: Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability study of metadoxine extended release (MDX) in adolescents with ADHD (predominantly inattentive type) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Metadoxine Extended Release (MDX) (metadoxine)

Snippet

Sponsor: Alcobra Ltd. | Conditions: ADHD, Predominantly Inattentive Type | Phase 2 | Status: COMPLETED